Button Adrian
Known title: EVP, Product and Service OpsCIK: 0001729263
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Goldman Sachs cuts NCR Voyix price target to $8. Goldman Sachs maintained a Neutral rating on NCR Voyix but lowered its price target to $8. This action follows the company's recent Q2 2026 earnings call. The new target is below the current average analyst estimate of $12.96, reflecting a cautious outlook from the firm.
Transaction History
| BCO | ▲ Buy | Grant | 4,943 | $0 | 3/2/2026 | View on chart |
| VYX | ▲ Buy | Option Exercise | 9,215 | $0 | 1/3/2023 | View on chart |
| VYX | ▼ Sell | Tax Withholding | 4,156 | $97K | 1/3/2023 | View on chart |
| VYX | ▲ Buy | Option Exercise | 100,441 | $0 | 12/16/2022 | View on chart |
| VYX | ▼ Sell | Tax Withholding | 45,299 | $1.0M | 12/16/2022 | View on chart |
| VYX | ▼ Sell | Open Market | 13,000 | $265K | 10/28/2022 | View on chart |
| VYX | ▲ Buy | Option Exercise | 21,712 | $574K | 2/18/2022 | View on chart |
| VYX | ▼ Sell | Open Market | 21,712 | $916K | 2/18/2022 | View on chart |
| VYX | ▲ Buy | Option Exercise | 30,540 | $0 | 2/8/2022 | View on chart |
| VYX | ▼ Sell | Tax Withholding | 9,953 | $381K | 2/8/2022 | View on chart |
| VYX | ▼ Sell | Tax Withholding | 28,657 | $1.2M | 12/31/2021 | View on chart |
| VYX | ▲ Buy | Option Exercise | 23,724 | $627K | 10/29/2021 | View on chart |
| VYX | ▼ Sell | Open Market | 23,724 | $938K | 10/29/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Brink's Gets CMA Approval for NCR Atleos Deal Remedy
Brink's received acceptance in principle from the UK's CMA regarding a proposed remedy for its pending acquisition of NCR Atleos. The company also reported Q2 2026 results and confirmed that a potential sale of UK assets will not impact expected $200M in annual synergies. This regulatory progress is a key step in finalizing the transaction.
Brink's Gets CMA Approval for NCR Atleos Deal Remedy. Brink's received acceptance in principle from the UK's CMA regarding a proposed remedy for its pending acquisition of NCR Atleos. The company also reported Q2 2026 results and confirmed that a potential sale of UK assets will not impact expected $200M in annual synergies. This regulatory progress is a key step in finalizing the transaction.